197TiP First-in-human (FIH) phase I/II study of ubamatamab, a MUC16xCD3 bispecific antibody, administered alone or in combination with cemiplimab in patients with recurrent ovarian cancer (OC)

Authors :: K.N. Moore
S. Bouberhan
E. Hamilton
J. Liu
R.E. O'Cearbhaill
D. O'Malley
K. Papadimitriou
D. Schröder
E. Van Nieuwenhuysen
S-Y. Yoo
M. Peterman
P. Goncalves
T. Schmidt
M. Zhu
I. Lowy
T. Uldrick
E.A. Miller
Source :: Immuno-Oncology and Technology. 16:100309
Publication Year :: 2022
Publisher :: Elsevier BV, 2022.

Tools